iShares Biotechnology ETF (NASDAQ:IBB) Shares Sold by Chesley Taft & Associates LLC

Chesley Taft & Associates LLC lessened its stake in iShares Biotechnology ETF (NASDAQ:IBB) by 18.0% in the fourth quarter, Holdings Channel reports. The institutional investor owned 26,698 shares of the financial services provider’s stock after selling 5,860 shares during the quarter. Chesley Taft & Associates LLC’s holdings in iShares Biotechnology ETF were worth $3,530,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Darwin Wealth Management LLC bought a new position in iShares Biotechnology ETF during the 3rd quarter worth approximately $29,000. Highline Wealth Partners LLC acquired a new stake in shares of iShares Biotechnology ETF during the 3rd quarter valued at approximately $30,000. Ashton Thomas Securities LLC bought a new position in iShares Biotechnology ETF during the third quarter worth $36,000. Modus Advisors LLC acquired a new position in iShares Biotechnology ETF in the fourth quarter worth $41,000. Finally, Voisard Asset Management Group Inc. bought a new stake in iShares Biotechnology ETF during the third quarter valued at $59,000. 62.45% of the stock is owned by institutional investors and hedge funds.

iShares Biotechnology ETF Price Performance

Shares of NASDAQ:IBB opened at $132.65 on Tuesday. iShares Biotechnology ETF has a 1-year low of $123.60 and a 1-year high of $150.57. The company’s fifty day moving average is $136.32 and its two-hundred day moving average is $141.84.

iShares Biotechnology ETF Cuts Dividend

The business also recently announced a dividend, which was paid on Friday, December 20th. Shareholders of record on Tuesday, December 17th were paid a $0.0624 dividend. The ex-dividend date was Tuesday, December 17th.

iShares Biotechnology ETF Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.